120 results about "TLR4" patented technology

The invention belongs to the field of compositions, and particularly relates to an anti-colitis composition and application, the anti-colitis composition comprises bacillus natto JLNA2301 bacterial liquid and ginseng water-soluble dietary fiber; the preservation number of the bacillus natto JLNA2301 is CGMCC (China General Microbiological Culture Collection Center) No. 27770; the volume mass ratio of the bacillus natto JLNA2301 bacterial liquid to the ginseng water-soluble dietary fibers in the composition is (8-10) mL: (0.25-1) g, and the viable count of the bacillus natto JLNA2301 bacterial liquid is 1 * 10 < 8 >-1 * 10 < 10 > CFU / mL; the composition can be used for preventing and treating colon shortening and bleeding caused by ulcerative colitis, repairing intestinal barrier protein and inhibiting a TLR4 / NF-kappa B inflammation pathway; the intestinal flora structure is regulated in a prevention period and a treatment period.

The invention belongs to the technical field of animal immunopotentiators, and particularly relates to an oil-in-water type veterinary adjuvant and a preparation method thereof. The oil-in-water type veterinary adjuvant comprises white oil, span 80, Tween 80, PEG400, astragalus polysaccharide and a phosphate buffer solution, the astragalus polysaccharide cooperates with a surfactant to activate a TLR4 / NF-kappa B pathway, Th1 / Th2 / Th17 three-way immune response is achieved, the serum IgG and mucous membrane sIgA antibody level is remarkably improved, and the problems that a traditional O / W adjuvant is high in layering rate (smaller than 5%), and the stability of the traditional O / W adjuvant is poor are solved through compound optimization of the HLB value (HLB = 11.5-12.0) of the HLB value of span 80 and Tween 80. And storage at 4 DEG C for 90 days) and poor freeze-thaw stability are solved.

The invention relates to the technical field of medicinal chemistry, and provides a TLR4 agonist, application thereof and a vaccine composition. The TLR4 agonist is a compound with a structure as shown in a formula 1 or a pharmaceutically acceptable salt thereof, the compound is glucosamine aminoalkyl 4-phosphate series molecules derived from MPL-12 structure modification, and the series molecules have enhanced immunostimulatory activity and selective immune response induction capability.

The application discloses a virtual screening method of a small-molecule compound targeting TLR4. The application screens potential compounds capable of combining with TLR4 through three-dimensional molecular docking, and preliminarily proves that three compounds, Z1410232649, F27210326 and HY-N0029, have better TLR4 inhibiting effects through experimental verification. Among them, Z1410232649 performs most outstandingly, can significantly inhibit the release of inflammatory factors IL-6, TNF-alpha and IFN-gamma induced by LPS, and can be used as a novel anti-inflammatory drug or immunotherapy drug targeting TLR4.

The invention provides application of PRP-Exos in preparation of a medicine for treating neuropathic pain, and relates to the technical field of clinical medicine. According to the invention, the treatment effect of PRP-Exos on neuropathic pain by inhibiting a TLR4 / NF-kappa B signal channel is clarified, a new thought is provided for clinical transformation, meanwhile, an intrathecal injection delivery mode is adopted, the limitation of low bioavailability of peripheral administration is overcome, meanwhile, the treatment effect is comprehensively verified through a behavioral-histological-molecular biological multi-modal evaluation system, and the application prospect is wide. The potential of the PRP-Exos in relieving the neuropathic pain is proved.

This invention provides the use of Yigongsan in the treatment of myelodysplastic syndrome (MDS). Specifically, this invention has found that Yigongsan improves ineffective hematopoiesis in MDS patients and significantly alleviates traditional Chinese medicine symptoms of MDS, such as fatigue, lethargy, lack of thirst, and sallow complexion. Furthermore, it has been discovered that Yigongsan regulates hematopoietic function in MDS through the S100A9-TLR4-NF-κB signaling pathway. This invention also provides a treatment method for MDS.

The invention discloses a manganese-based nano-enzyme composite material as well as a preparation method and application thereof. The preparation method comprises the following steps: (1) preparing Mn3O4-PVP from Mn3O4 NPs and PVP10, and then loading the Mn3O4-PVP into a ZIF-8 structure in the process that Zn < 2 + > and 2-MI react to form ZIF-8, so as to obtain Mn3O4-coated ZIF-8 NPs; (2) covering the surface of the Mn3O4 ZIF-8 with HA through ion coordination, and synthesizing MZH; and (3) carrying out clathration on MZH through ES100, and synthesizing MZH coated ES100. By inhibiting a TLR4 / NF-kappa B pathway, activating an Nfr2 / Keap1 pathway and increasing expression of intestinal tight junction protein, mouse colitis induced by DSS is resisted, and symptoms of the mouse colitis are relieved.

The application discloses application of Bifidobacterium longum exopolysaccharide or a co-incubation extractive solution of the Bifidobacterium longum exopolysaccharide and probiotics in improving inflammation. The application finds that the Bifidobacterium longum exopolysaccharide and the co-incubation extractive solution of the Bifidobacterium longum exopolysaccharide and Lactobacillus acidophilus can inhibit LPS-induced TLR4 / NfkB (P65) signal path activation, inhibit the polarization of macrophages from M0 to M1, thereby inhibiting inflammatory reactions, and the inhibiting effect of the co-incubation extractive solution of the Bifidobacterium longum exopolysaccharide and Lactobacillus acidophilus is more obvious. Therefore, the Bifidobacterium longum exopolysaccharide and the co-incubation extractive solution of the Bifidobacterium longum exopolysaccharide and Lactobacillus acidophilus can be used for preparing drugs for inhibiting inflammatory reactions, and are helpful to the treatment of immune and chronic inflammatory diseases and the development of related drugs.

The application discloses an application of a TLR4 / NF-kappa B signal path inhibitor in preparation of a medicine for improving hematopoietic function of anemic inflammatory, relates to the technical field of biology and medicine, and discloses an application of the TLR4 / NF-kappa B signal path inhibitor in preparation of a medicine for improving hematopoietic function of anemic inflammatory, wherein the TLR4 / NF-kappa B signal path inhibitor is Danggui Buxue Decoction; the Danggui Buxue Decoction is composed of Astragalus and Angelica with a mass ratio of 5:1; the TLR4 / NF-kappa B signal path inhibitor is used for down-regulating expression of TLR4 protein and NF-kappa B protein in liver tissue; the improvement of hematopoietic function of anemic inflammatory includes increasing peripheral blood red blood cell count, white blood cell count, platelet count and hemoglobin level; the Danggui Buxue Decoction is used as the TLR4 / NF-kappa B inhibitor to improve anemic inflammatory, can down-regulate TLR4 / NF-kappa B expression, improve blood cells and hemoglobin, improve bone marrow pathology, reduce inflammatory factors and hepcidin, increase iron content, and provide a corresponding curative effect evaluation method, and provides a new choice for anemic inflammatory treatment.

The invention belongs to the field of polypeptides, and particularly relates to a TLR4 binding peptide and application thereof. The specific technical scheme is as follows: the nucleotide sequence of the polypeptide is edited as shown in SEQ ID NO: 1. The binding peptide containing 67 amino acids is screened out, is good in solubility, can be stably bound with TLR4, and is expected to become a new medicine for treating or relieving pain including chronic pain. The polypeptide can also be prepared into health care products, special medical foods and the like with the function of treating or relieving pain according to actual conditions.

The present disclosure relates to the use of compound (I) and any of its salts for the treatment of a neoplasm characterized by high expression of toll-like receptor 4 (TLR4) in the tumor or its microenvironment, associated with at least one of the pathophysiological complications including immunosuppression, angiogenesis, fibrosis, or metastasis.

The invention provides lactobacillus plantarum S7-12, fermented vegetables and application of the lactobacillus plantarum S7-12 and the fermented vegetables, and belongs to the technical field of microbial fermentation, the lactobacillus plantarum S7-12 is preserved in Guangdong Microbial Culture Collection Center, and the preservation number is GDMCC No: 66578. The plant lactobacillus S7-12 has relatively strong growth ability, acid production ability, acid resistance and salt resistance, and fermented vegetables prepared from the plant lactobacillus S7-12 can be used for relieving weight loss and colon shortening caused by inflammatory bowel diseases, reducing disease activity indexes and visceral organ indexes, relieving intestinal mucosa structural damage, relieving oxidative stress injury of colon, and improving the immunity of the vegetables. The release of proinflammatory factors in serum and colon is reduced, the secretion of anti-inflammatory factors is improved, the expression quantity of colon tight junction protein is increased, the TLR4 pathway is activated, and the colon barrier function is improved; the method can be used for preparing health-care foods or medicines, and has a wide application prospect.

Stable aqueous formulations of adjuvant comprising a TLR7 / 8 agonist or a TLR4 agonist with a helper lipid that are adsorbed to alum are provided. Compositions and methods of using the formulations for stimulating an immune response are also provided.

The invention discloses a traditional Chinese medicine composition for inhibiting salmonella choleraesuis as well as a preparation and application thereof, and belongs to the technical field of traditional Chinese medicine and network pharmacology. According to the invention, traditional Chinese medicines with a good antibacterial effect on S. Choletaesuis are screened, and the compound five-plum decoction with a good antibacterial effect on S. Choletaesuis is established. The five-plum decoction can be used for effectively regulating and controlling the steady state of intestinal flora, and reducing the oxidative damage and inflammatory damage of the S. Cholera to the intestinal tract and the liver by regulating and controlling the signal channels of TLR4 / NF-kB / MyD88 and ZO-1 / Claudin-1 / Occludin. Through the multiple effects of resisting bacteria, resisting inflammation, protecting intestinal barriers and improving production performance, the five-plum decoction shows remarkable prevention and treatment effects on swine paratyphoid, and has huge value of being developed into a novel veterinary traditional Chinese medicine preparation and put into clinical application.

The invention provides a process for preparing a Biochanin A (BCA)-loaded hydroxypropyl methyl cellulose (HPMC) hydrogel aimed at promoting wound healing in diabetic patients. The hydrogel is prepared by dispersing HPMC in distilled water, followed by dissolving BCA into the mixture with continuous stirring, then storing under refrigeration. The therapeutic potential of Biochanin A (BCA) in promoting wound healing, is evaluated in rats induced with diabetes. The results showed that the BCA-loaded hydrogel accelerates diabetic wound repair by boosting antioxidant defenses via upregulating Nrf2 and related enzymes, suppressing inflammatory markers such as IL-1β, IL-6, TNF-α, COX-2, and TLR4, and stimulating angiogenesis through increased expression of TGF-β1, VEGF-A, and PDGFR. It promotes faster wound contraction, re-epithelialization, collagen deposition, granulation tissue formation, and neovascularization, potentially reducing the risk of complications like limb amputation. The invention offers a promising therapeutic approach for treating chronic diabetic wounds with improved healing outcomes.

The invention relates to application of rosa rugosa in preparation of a medicine for treating IBD (infectious bursal disease). According to the invention, firstly, it is found that the branchlet rose has a repairing effect on damage caused by IBD; researches find that the aqueous extract of rugosa branchlet can play a role by repairing intestinal barriers and inhibiting TLR4, TLR9 and proinflammatory cytokines, so that the aqueous extract of rugosa branchlet is beneficial to treatment of IBD. The invention provides an application prospect of the rosa rugosa in preparation of the medicine for treating IBD.

The invention provides an application of alkaloid bicuculline in preparation of a medicine for preventing and / or treating hepatic fibrosis diseases and hepatic inflammation, and also provides an application of bicuculline in preparation of an inflammatory factor expression inhibitor and an application of bicuculline in preparation of a Toll-like receptor 4 signal channel inhibitor. 7.5 mu g / mL of bicuculline can be used for relieving the activation of hepatic stellate cells induced by TGF-beta1, remarkably reducing the expression of alpha-SMA and COL1A1, and reducing the expression of MyD88 and NF-kB as well as downstream inflammatory factors IL-6, IL-1beta and TNF-alpha in a TLR4 / MyD88 / NF-kB signal channel. By intraperitoneal injection treatment of 0.6 mg / kg of bicuculline, the liver morphology in a fibrosis model can be remarkably improved, the levels of ALT and AST in serum can be remarkably reduced, and collagen deposition and expression of alpha-SMA and COL1A1 in the liver can be remarkably reduced.

The invention belongs to the technical field of gene engineering, and provides Hsp60 receptor targeted recombinant lactobacillus plantarum as well as a construction method and application thereof, lactobacillus plantarum is taken as a host, pPG612 is taken as an expression vector, and CsgB gene or CsgF gene is expressed. The two engineering probiotics can express target protein and can be stably expressed on the surfaces of thalli, the AB.9 intestinal epithelial cells can be effectively adhered, and the adhesion and invasion of the A.veronii to the AB.9 cells can be inhibited. And secondly, the engineering probiotics LP-pPG-CsgB and LP-pPG-CsgF can promote the proliferation of dendritic cells, T lymphocytes and B lymphocytes, and improve the IgT secretion of intestinal mucus. The engineering bacteria can be competitively combined with an intestinal epithelial cell Hsp60 receptor, down-regulate p65 expression, inhibit NF-kappa B signal channel activation, regulate intestinal tight junction protein redistribution and down-regulate proinflammatory factor expression through a TLR4 / TLR5 dependent NF-kappa B signal channel, and the engineering bacteria can increase the abundance of effective microbial communities in the intestinal tract of the snakeheaded fish, so that the growth of the snakeheaded fish is promoted, and the growth of the snakeheaded fish is promoted. And the flora can transfer, mediate and activate immune response through a feeding environment.

The present application relates to the technical field of biological medicine, in particular to application of aconitum brachypodum franch alcohol extract in myocardial protection, and discloses that the aconitum brachypodum franch alcohol extract mainly inhibits formation of myocardial fibrosis, reduces inflammatory reaction and reduces cell apoptosis by adjusting a TLR4 / MyD88 / NF-kappa B channel, thereby protecting ISO-induced myocardial injury of a mouse; the present application provides a theoretical basis for improving myocardial injury by the aconitum brachypodum franch, and also provides a scientific basis for development and utilization of the aconitum brachypodum franch.

The invention discloses a tuna red meat immunity enhancing peptide and application thereof in enhancing immunity, and belongs to the technical field of biology. According to the invention, polypeptides with immunocompetence are extracted from tuna red meat, and the polypeptides comprise FLQGF and LAKFPDF. Experiments prove that the polypeptide prepared by the invention has no obvious toxic effect on cells, and can improve the proliferation rate and the phagocytic rate of macrophages and the release rate of NO to different degrees. An in-vitro immunomodulatory activity result shows that the LAKFPDF and the FLQGF can activate a TLR4 dependent NF-kB / MAPK signal channel, regulate and control the immune response of macrophages and play an immunomodulatory role. Research results of the invention provide a basis for high-value development and utilization of tuna red meat, and provide a new resource for preparation of immunopotentiation products.

The invention provides a traditional Chinese medicine composition, a traditional Chinese medicine preparation, a preparation method and application, and particularly belongs to the technical field of traditional Chinese medicine preparation. The traditional Chinese medicine composition comprises the following components in parts by weight: 7-11 parts of champignon, 19-29 parts of aloe, 10-14 parts of fructus chebulae immaturus, 5-7 parts of rhizoma zingiberis, 5-7 parts of rhizoma nardostachyos, 4-6 parts of fructus chebulae and 2-4 parts of halite. The traditional Chinese medicine composition can improve the activity of SOD, inhibit the content of MDA, reduce damage of oxygen free radicals to gastric mucosa, effectively relieve inflammatory response, achieve anti-inflammation, improve ulcer surface blood flow, improve gastric mucosa damage, reduce ulcer surfaces and promote ulcer healing, and therefore the protective effect on gastric ulcer is achieved. The results of network pharmacology, molecular docking speculation and Western blot method verification show that the FMST plays an anti-inflammatory role through a TLR4 / MyD88 / NF-kappa B signal channel.

The present application relates to triterpene glycoside saponin-derived adjuvants, TLR4 agonists and antagonists, TLR9 agonists and antagonists, and combinations thereof, as well as pharmaceutical compositions comprising the foregoing and methods of making and of using the foregoing in the treatment of certain diseases.

The invention belongs to the technical field of biological medicine, and particularly relates to coriaria sinica lactone compounds, a preparation method thereof and application of the coriaria sinica lactone compounds in anti-inflammatory activity. The coriaria sinica lactone compound can significantly inhibit a TLR4 / NF-kappa B signal channel to inhibit downstream inflammatory protein nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) and further inhibit inflammatory BV2 cells from generating nitric oxide, the inhibition rate can reach 65.5%, and it is indicated that the coriaria sinica lactone compound has an application prospect in treatment of neuroinflammatory diseases.

The invention discloses application of AvBD-5 protein in resisting avian influenza virus infection, and belongs to the technical field of biology. A recombinant plasmid containing a coding sequence of the AvBD-5 protein is transformed into an escherichia coli expression system, IPTG is used for inducing expression of the AvBD-5 protein, the expressed AvBD-5 protein is purified, the high-concentration purified AvBD-5 protein is obtained through ultrafiltration and concentration, the protein can remarkably reduce the virus load of the H9N2 avian influenza virus in in-vivo and in-vitro experiments, and the virus load of the H9N2 avian influenza virus can be remarkably reduced. Meanwhile, the polypeptide has a prominent immunoregulation function, and can specifically inhibit the expression of TLR4 and block the activation of a TLR4 / NF-kappa B signal channel by regulating the immunologic function of red blood cells. The protein can be used as a novel immunomodulator or a drug candidate, and is used for preventing and treating H9N2 avian influenza virus infection.

The application discloses an application of ergothioneine in antiviral in the field of biotechnology. The ergothioneine plays an immune activation role at least by activating TLR4 and downstream NF-kappa B signal pathways. The ergothioneine is used for preparing an immunomodulator or an antiviral drug, can effectively activate immune cells and enhance antiviral capacity, to a certain extent, overcomes defects of traditional technologies, reduces problems of large side effects of current TLR4 agonists, and provides a new idea for developing a novel immunomodulator and an antiviral treatment strategy.

The present invention discloses a baicalein derivative, its preparation method, and application. The baicalein derivative is 4'-methylamino baicalein. Experimental results demonstrate that the MAB described herein is not only low in toxicity but also exhibits a more significant inhibitory effect on excessive inflammatory responses induced by LPS or pathogenic bacteria infection than baicalein under the same conditions, and exhibits superior targeting ability to TLR4 protein. Therefore, it is expected that the MAB, or at least one of its pharmaceutically acceptable salts, tautomers, stereoisomers, and precursor compounds, may be used as an active ingredient in the preparation of a drug for the treatment of sepsis.

The present invention refers to inhibitors of the S100 calcium- binding protein A9 (S100A9) / S100A8 – Toll Like Receptor 4(TLR4) dimer-receptor axis for use in the treatment of Heart Failure with preserved Ejection Fraction (HFpEF). The present invention further refers to pharmaceutical formulations comprising the said inhibitors. The present invention's use of compounds and pharmaceutical formulations may be advantageously employed in HFpEF by attenuating the deleterious effect on endothelial function and prevention of inflammation, production of reactive oxygen species, apoptosis, senescence and pro-fibrotic phenotype.

The invention discloses an application of a C21 steroid compound in preparation of an anti-inflammatory product. The C21 steroid compound comprises a compound as shown in a formula I which is described in the specification. The C21 steroid compound has an excellent anti-inflammatory effect, and can reduce expression of inflammatory proteins such as TNF-alpha, COX-2, iNOS, IL-1beta, TLR4, p38, ERK and JNK by inhibiting activation of signaling pathway related factors such as TLR4 / NF-kappa B and MAPK, so that generation and release of inflammatory factors are reduced to play a role.

The present invention relates to liposomes comprising a saponin, a sterol, a phospholipid and a Toll-like Receptor 4 (TLR4) agonist of formula (I), methods of preparing the liposomes, compositions comprising them and uses thereof, and immunogenic compositions comprising said liposomes as adjuvants.

A method to enhance an immune response in a mammal, and a composition comprising liposomes, a TLR4 agonist and a TLR7 agonist, are provided.